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INTRODUCTION
Coxiella burnetii is an obligate intracellular bacte-
rium causing Q-fever, a zoonotic disease that is
ubiquitous throughout the world with the excep-
tion of New Zealand. Cattle, goats, sheep and
ticks are the primary reservoirs, but many other
species, including ﬁsh, birds, rodents and cats, are
known to become infected. Especially in small
ruminants, infection can lead to abortion associ-
ated with exceptionally high amounts of C. bur-
netii in amniotic ﬂuids and the placenta.
Furthermore, C. burnetii may be excreted in milk,
urine and faeces of infected animals. Human
infections frequently follow contact with infected
sheep, especially during lambing, or via the
inhalation of dried tick faeces during shearing.
Most cases of human infection with C. burnetii
are self-limiting, associated with fever, fatigue,
headache and myalgia. Acute Q-fever is fre-
quently accompanied by atypical pneumonia
and ⁄ or hepatitis. Persistence of infection exceed-
ing 6 months in duration is regarded as chronic
Q-fever. Commonly, endocarditis is seen, but
chronic hepatitis, osteomyelitis, septic arthritis
or infection of aneurysm and vascular grafts can
also occur. During pregnancy, Q-fever has been
associated with premature birth, abortion and
neonatal death.
Diagnosis mostly relies on serology, but, espe-
cially in the early clinical stages, PCR offers
substantial beneﬁts for the identiﬁcation of C. bur-
netii infection [1].
In our study, we investigated the suitability of a
new rapid ‘low cost and density’ (LCD) DNA
microarray chip for the detection of C. burnetii
(Coxiella 2.5). Besides the commonly used IS1111
genomic target (Genebank accession number:
M80806), we coated a recently described genomic
marker proposed to be diagnostic of acute Q-fever
(acute disease antigen A (adaA), CBU_0952, Gen-
Bank ID AAO90475.1) on the chip [2]. The results
were compared with those of both conventional,
gel-based and a real-time LightCyclerHyprobe–
PCR assay in terms of speciﬁcity and sensitivity.
Clinical materials of both human and animal
origin were also used for evaluation.
MATERIALS AND METHODS
We investigated 22 C. burnetii isolates from either humans or
from animal species (Table 1). DNA was prepared from heat-
inactivated cell culture material using the cell culture prepa-
ration-kit (MagNA Pure Compact; Roche, Mannheim, Ger-
many). In addition, two human clinical samples and 50
samples from goats, sheep and cattle were assessed. DNA
was prepared with a standard kit (DNA-Mini; Qiagen, Hilden,
Germany). Speciﬁcity was assessed by using a DNA panel of
16 related bacteria. Sensitivity was determined by a dilution
series of the IS1111 and adaA plasmid standards provided with
the kit.
The LCD-Array Coxiella 2.5 Kit consists of a DNA micro-
array chip constructed from a transparent pre-structured
polymer support slide (50 · 50 mm) containing eight identical
hybridization ﬁelds spotted with immobilized IS1111 or adaA
gene oligonucleotides (IS1111 probe 1, gATCgTAACgATgCg-
CAggC; IS1111 probe 2, gAACCATTggTATCggACgTTTATg;
adaA probe 1, CTgAgCTgCgCCAgCgAg; adaA probe 2, AA-
gAATTAACgCTAATgCgATCTgC). All Coxiella-speciﬁc oligo-
nucleotides were printed in duplicate. Three spots served as
hybridization, staining and internal (lambda phage) inhibition
controls. Visualization was achieved using a precipitation
substrate (biotin–avidin complex) permitting easy inter-
pretation by the naked eye. All primer solutions (IS1111-
Mix F, 5¢-ggTAAAgTgATCTACACgAgACgg; IS1111-Mix R,
5¢-BIO-TCTTTAACAgCgCTTgAACgTC; adaA-Mix F, 5¢-AAT
AgATTCgCTCTCTCAAgCCg; adaA-Mix R, 5¢-BIO-ggTTT
CTTCCCAAAgTCACCg; lambda-Mix F, 5¢-ATgCCACgTAA
gCgAAACA; lambda-Mix R, 5¢-BIO-gCATAAACgAAgCA
gTCgAgT), controls (IS1111 and adaA plasmid standards and
lambda phage) are included in this ready-to-use kit. Following
the PCR ampliﬁcation step, material was simultaneously
processed on the LCD array (hybridization, labelling and
staining) and with both conventional and real-time LightCy-
clerHyprobe–PCR for conﬁrmation (the latter techniques are
described elsewhere [2,3]).
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RESULTS
All 22 C. burnetii isolates from animals and
humans, regardless of whether they were from
acute or chronic disease, yielded positive reac-
tions with both probes in each PCR platform, with
the exception of one human chronic disease-
derived and one animal-derived isolate that failed
to react with adaA regardless of the platform used
(Table 1). C. burnetii DNA could be detected in
different clinical matrices, including sputum,
placental tissues, milk, faeces, and vaginal secre-
tions (results not shown). The detection limit was
10 genomic copies per microlitre for IS1111 and
100 copies for adaA respectively for all three PCR
methods. No detectable reactions were seen with
DNA panels of 16 related bacteria, or 14 clinical
samples from non-infected animal species or from
uninoculated cell culture material. Thus, tradi-
tional and new PCR methods showed no differ-
ence according to sensitivity and speciﬁcity
(100%).
CONCLUSION
This novel technique allows rapid (45 min with
15 min of ‘hands-on’ time only), sensitive, speciﬁc
and economic detection of PCR-ampliﬁed prod-
ucts. Pure isolates and clinical material of human
and veterinary origin could be successfully anal-
ysed. The LCD chip kit can be used in routine
laboratories, as it does not require sophisticated
equipment. Its low cost and simplicity make this
diagnostic approach favourable for ﬁeld or epi-
demiological studies in developing countries. In
addition, we showed in this study that the adaA
gene occurs in acute human Q-fever isolates.
Nevertheless, further investigations of a larger
collection, especially with chronic isolates, is
recommended to conﬁrm the value of this new
acute disease marker.
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Table 1. Coxiella burnetii isolates tested
Strains Source/Origin IS1111 adaA
Geier Human, pneumonia, Romania + +
CS-Florian Human, blood, Slovakia, 1954 + +
Herzberg Human, Greece + +
Balaceanu Human, pneumonia, Romania + +
Brasov Human, pneumonia, Romania + +
Henzerling Human, blood, Italy, 1945 + +
F-1 Human, endocarditis, France, 1992 + )
CS-S1 Cow, Slovakia, 1970 + +
CS-KL 1 Tick, Slovakia + +
CS-KL 5 Tick, Slovakia + +
Nine Mile Tick, USA, 1938 + +
Z2534 ⁄ 90 Goat, Austria, 1990 + +
Hardthof ⁄ 90 Cow, Germany, 1990 + +
S-1 Sheep, Sweden, 1990 + +
Z3749 ⁄ 92 Cow, Germany, 1992 + +
Z104 ⁄ 94 Sheep, Germany, 1994 + +
Z257 ⁄ 94 Cow, Germany, 1994 + +
J-1 Cow, Japan + +
Frankfurt Cow, Germany, 1982 + +
Mu¨nchen Sheep, Germany, 1969 + +
Priscilla Goat, USA, 1980 + )
Dugway Rodents, USA, 1958 + +
+, ampliﬁcation of IS1111 or adaA gene sequences; ), no ampliﬁcation.
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